Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas.

Physiological research - 1 Jan 2012

Schroner Z, Javorský M, Halušková J, Klimčáková L, Babjaková E, Fabianová M, Slabá E, Kozárová M, Tkáč I

Abstract excerpt

The aim of the present pilot pharmacogenetic study was to analyse quantitative effects of sulphonylurea treatment in addition to metformin on parameters of glycemic control with respect to CDKAL1 genotypes in patients with type 2 diabetes. Effect of 6-month sulphonylurea therapy on glycemic control according to CDKAL1 genotypes was evaluated in 101 patients with type 2 diabetes who failed to achieve glycemic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Blood Glucose
Share to Cyclin-Dependent Kinase 5

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Hypoglycemic Agents

Share to Metformin

Share to Sulfonylurea Compounds

Share to tRNA Methyltransferases

Source

Identifiers

PMID: 22292718
DOI: 10.33549/physiolres.932228

Genes

CDKAL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas.PMID 22292718Read ↗

Variation in KCNQ1 is associated with therapeutic response to sulphonylureas.Semantic proximity Read ↗

The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel.Semantic proximity Read ↗

Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China.Semantic proximity Read ↗

Genetic Variants Identified from GWAS for Predisposition to Type 2 Diabetes Predict Sulfonylurea Drug Response.Semantic proximity Read ↗

Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics.Semantic proximity Read ↗

A Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa Japan.Semantic proximity Read ↗

Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetesSemantic proximity Read ↗

Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.Semantic proximity Read ↗

Impact of PRKAA2 and LKB1 genetic variants on metabolic alterations in response to metformin-sulfonylurea therapy.Semantic proximity Read ↗

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.Semantic proximity Read ↗

Combined Influence of Genetic Variants and Gene-gene Interaction on Sulfonylurea Efficacy in Type 2 Diabetic Patients.Semantic proximity Read ↗

Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical careSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.